info@seagull-health.com
SeagullHealth
语言:
search
new
What is Tirzepatide?
502
Article source: Seagull Pharmacy
Dec 08, 2025

Tirzepatide is a novel dual receptor agonist classified as a long-acting GIP/GLP-1 receptor agonist. As a significant breakthrough in the treatment of type 2 diabetes mellitus, its unique dual mechanism of action and remarkable glucose-lowering and weight-reducing effects have garnered considerable clinical attention.

What is Tirzepatide?

Pharmacological Actions

Tirzepatide exerts a synergistic glucose-lowering effect by simultaneously activating the GIP receptor and GLP-1 receptor.

Its molecular structure consists of 39 amino acids, and it binds to endogenous albumin via a C20 fatty acid side chain, significantly extending its half-life and enabling once-weekly administration.

The medication promotes insulin secretion in a glucose concentration-dependent manner, inhibits glucagon secretion, and improves insulin sensitivity.

Indication Scope

This product is indicated for blood glucose control in patients with type 2 diabetes mellitus, but only when the effects of adequate dietary therapy and exercise therapy remain unsatisfactory.

It is important to note that this medication is not a substitute for insulin, and the patient’s insulin-dependent status must be strictly evaluated before use.

Specifications and Properties of Tirzepatide

Specification Description

All strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) are supplied as 0.5 mL of solution per prefilled pen, with each box containing two injection pens.

Property Description

Formulation Type: Combined product consisting of a prefilled syringe with a fixed injection needle and an injector.

Appearance: Colorless to slightly yellowish to slightly brownish clear liquid, or liquid with a slight milky luster.

pH Value: 6.5–7.5.

Osmolality Ratio: Approximately 1 (relative to physiological saline).

Composition

Active Ingredient: Tirzepatide (content corresponding to each strength).

Excipients: Disodium hydrogen phosphate heptahydrate 0.7 mg, sodium chloride 4.1 mg.

pH Adjusters: Hydrochloric acid (as needed), sodium hydroxide (as needed).

Storage Conditions of Tirzepatide

Storage Environment Requirements

Routine Storage: Store at 2–8℃ in the dark.

Room Temperature Storage: May be stored at room temperature below 30℃, but the outer packaging must be retained, and the product must be used within 21 days.

Shelf Life: 24 months.

Prohibition: Avoid freezing; do not use if frozen crystals form.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Mounjaro(Tirzepatide)
Mounjaro(Tirzepatide)
Adults with type 2 diabetes mellitus, specifically for improving glycemic...
WeChat Scan
Free Inquiry
Recommended Articles
How to Purchase Tirzepatide
Tirzepatide is a novel dual GIP/GLP-1 receptor agonist that has demonstrated breakthrough efficacy in the treatment of type 2 diabetes mellitus. As a strictly regulated prescription drug, its acquisit...
What are the Side Effects of Ticagrelor (Brilinta)?
Ticagrelor (Brilinta) is a novel antiplatelet agent with ticagrelor as its active ingredient. By reversibly inhibiting the P2Y12 receptor, it effectively blocks ADP-induced platelet aggregation. This ...
How to Use Ticagrelor (Brilinta)
Ticagrelor (Brilinta) is a selective, reversible P2Y12 receptor antagonist belonging to the class of novel antiplatelet agents. By blocking ADP-mediated platelet activation, this medication effectivel...
What is Ticagrelor (Brilinta)?
Ticagrelor (Brilinta) is a novel antiplatelet agent that holds an important position in the treatment of cardiovascular diseases.What is Ticagrelor (Brilinta)?Acute Coronary Syndrome (ACS)Indicated fo...
How to Use Tirzepatide
Tirzepatide is a long-acting dual GIP/GLP-1 receptor agonist. It promotes insulin secretion and inhibits glucagon release through a glucose concentration-dependent mechanism, and is mainly used for bl...
What Are the Purchasing Channels for Canakinumab (Ilaris)?
Canakinumab (Ilaris) is a monoclonal antibody targeting interleukin-1β, mainly indicated for the treatment of various autoimmune diseases such as periodic fever syndromes, adult-onset and juvenile-ons...
What Are the Indications for Canakinumab (Ilaris)?
Canakinumab (Ilaris) is an important biological agent. As an interleukin-1β (IL-1β) blocker, it has extensive clinical application value.What Are the Indications for Canakinumab (Ilaris)?Cryopyrin-Ass...
Dosage and Administration, Recommended Doses of Canakinumab (Ilaris)
Canakinumab (Ilaris) is an interleukin-1β blocker indicated for the treatment of various autoinflammatory diseases.Dosage and Administration, Recommended Doses of Canakinumab (Ilaris)General Administr...
Related Articles
How to Use Tirzepatide
Tirzepatide is a long-acting dual GIP/GLP-1 receptor agonist. It promotes insulin secretion and inhibits glucagon release through a glucose concentration-dependent mechanism, and is mainly used for bl...
What is Tirzepatide?
Tirzepatide is a novel dual receptor agonist classified as a long-acting GIP/GLP-1 receptor agonist. As a significant breakthrough in the treatment of type 2 diabetes mellitus, its unique dual mechani...
How to Purchase Tirzepatide
Tirzepatide is a novel dual GIP/GLP-1 receptor agonist that has demonstrated breakthrough efficacy in the treatment of type 2 diabetes mellitus. As a strictly regulated prescription drug, its acquisit...
People who are contraindicated for the use of Tirzepatide
Tirzepatide is a dual agonist of glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor, which has a good therapeutic effect on adult type 2 diabetes. This ...
The latest data of Tirzepatide is released, and diabetic patients are expected to achieve efficient blood sugar control
The number of people with diabetes has increased dramatically in recent years. The World Health Organization (WHO) predicts that the number of patients will reach 642 million in 17 years, of which typ...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved